Home/Filings/4/0001567619-18-008244
4//SEC Filing

KANAN MICHAEL F 4

Accession 0001567619-18-008244

CIK 0001012477other

Filed

Dec 17, 7:00 PM ET

Accepted

Dec 18, 4:06 PM ET

Size

10.9 KB

Accession

0001567619-18-008244

Insider Transaction Report

Form 4
Period: 2018-12-14
KANAN MICHAEL F
See Remarks
Transactions
  • Sale

    ADSs

    2018-12-14$2.49/sh8,429$21,02229,538 total
Holdings
  • Stock Option (right to buy)

    Exercise: $16.21Exp: 2025-10-28ADSs (100,000 underlying)
    100,000
  • Stock Option (right to buy)

    Exercise: $10.40Exp: 2026-12-14ADSs (100,000 underlying)
    100,000
  • Stock Option (right to buy)

    Exercise: $8.95Exp: 2027-12-12ADSs (80,000 underlying)
    80,000
Footnotes (7)
  • [F1]The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.
  • [F2]On December 14, 2018, the reporting person sold 8,429 ADSs in connection with the payment of certain withholding taxes related to the vesting of restricted ADSs that were granted to the reporting person on December 14, 2016 (such grant was reported by the reporting person on a Form 4 filed on December 16, 2016).
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.4732 to $2.64, inclusive. The reporting person undertakes to provide to Avadel Pharmaceuticals plc, any security holder of Avadel Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3).
  • [F4]Includes (a) 18,000 ADSs granted under the issuer's "Free Share" award program as restricted ADSs on 12/14/2016, all of which were issued to the reporting person on the second anniversary of the grant date; in connection with the payment of certain withholding taxes related to such issuance, the reporting person sold 8,429 ADSs on December 14, 2018; and (b) 18,000 restricted shares granted under the issuer's Omnibus Incentive Compensation Plan on 12/12/2017, under which 12,000 ADSs will vest and be issued on the second anniversary of the grant date and the remaining 6,000 ADSs will vest and be issued on the third anniversary of the grant date (with vesting of these restricted shares subject to the reporting person remaining in continuous service until the applicable anniversary of the date of grant).
  • [F5]Options become exercisable as to 25,000 ADSs on each of the first four anniversaries after the 10/28/2015 grant date.
  • [F6]Options become exercisable as to 25,000 ADSs on each of the first four anniversaries after the 12/14/2016 grant date.
  • [F7]Options become exercisable as to 20,000 ADSs on each of the first four anniversaries after the 12/12/2017 grant date.

Documents

1 file

Issuer

AVADEL PHARMACEUTICALS PLC

CIK 0001012477

Entity typeother

Related Parties

1
  • filerCIK 0001461953

Filing Metadata

Form type
4
Filed
Dec 17, 7:00 PM ET
Accepted
Dec 18, 4:06 PM ET
Size
10.9 KB